Effects of Topical Calcipotriol on Calcium Metabolism in Psoriatic Patients: Comparison with Oral Calcitriol

Gumowski‐Sunek, D.; Rizzoli, René; Saurat, Jean‐Hilaire

doi:10.1159/000247699

Cited by 20 publications

(10 citation statements)

References 6 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mean values were within normal range after calcipotriol therapy, particularly 24-hour cal cium excretion which is a reflection of intestinal absorption and the fasting calcium-to-creatinine ratio which evaluates bone resorption. These parameters were not, for cost reasons, systemati cally evaluated in patients of groups 2 and 3, since this had been done previously in a similar type of patients [5].…”

Section: Resultsmentioning

confidence: 99%

“…In a previous study, we found that topical calcipotriol did not modify calcium metabolism when used in patients with psoriasis covering 16±6% of the body surface and receiving 25 g of ointment per week [5]. In contrast, 1.5 jig/ day of calcitriol orally for 7 days in the same patients in duced a significant increase in plasma levels of proteinadjusted calcium and in 24-hour urinary calcium excretion, as well as a significant fall in PTH [5|.…”

Section: Discussionmentioning

confidence: 99%

“…Despite similar in vitro potency with calcitriol [l,25-(OH),-D,] in various cell systems including bone cells [3.4], calcipotriol therapy was not associated with any detectable change in calcium metabolism, when applied at a dose of 100 g/ month over a mean body surface of 16% [5]; in contrast, oral calcitriol (1.5 jag/day) induced a significant increase in plasma levels of protein-adjusted calcium and in 24-hour urinary calcium excretion, as well as a significant fall in parathyroid hormone (PTH) as compared with pretreatment values [5]. However, that calcipotriol might affect calcium homeostasis when administered on large body surfaces and/or for prolonged periods of time remains to be eval uated.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Oral Calcium Tolerance Test in Extensive Psoriasis Treated with Topical Calcipotriol

Gumowski‐Sunek¹,

Rizzoli

Saurat³

1995

Dermatology

Self Cite

View full text Add to dashboard Cite

Background: The vitamin D₃ derivative calcipotriol (Daivonex®) is an efficient topical treatment of psoriasis. When applied at a dose of about 25 g/week over a mean body surface of 16%, it is not associated with any detectable change in calcium metabolism. Objective: Our purposes were (i) to analyze the effects of calcipotriol on various parameters of calcium metabolism when applied on a large body surface and (ii) to evaluate the usefulness of an oral calcium tolerance test in monitoring psoriatic patients under topical calcipotriol. Methods: In group 1, 10 patients with psoriasis affecting 67.0 ± 2.7% of total body surface (range 55–80%) were treated with calcipotriol for 6.5 weeks (mean 383 g/month). In group 2, 19 patients with psoriasis involving 15% of body surface were treated with calcipotriol for 9 weeks (mean 105 g/month). In group 3, 7 patients without topical calcipotriol for at least 1 week were given 1.5 μg of oral calcitriol for 7 days. An extended survey of blood and urinary parameters of calcium metabolism was performed before and after 45 days of treatment (group 1). Since one of the actions of vitamin D is to stimulate intestinal calcium absorption, an oral calcium-loading test (groups 1, 2 and 3) was done in order to detect more subtle changes possibly induced by calcipotriol. Results: We did not detect any significant change in various parameters of calcium metabolism in group 1 (large body surface treated) patients. The urinary calcium responses to the oral calcium load were identical to controls in both group 1 (large body surface treated) and group 2 (limited body surface treated), whereas in group 3 (oral calcitriol therapy) an increased urinary calcium response to the calcium load was identified. Conclusions: No significant changes in calcium metabolism were detectable when calcipotriol was administered once a day over a large body surface with doses up to 100 g/week. The oral calcium tolerance test appears to be a cheap, simple and sensitive test to monitor patients exposed to high doses of calcipotriol as it detects increased intestinal calcium absorption induced by 1.5 μg of oral calcitriol.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Calcium Tolerance Test in Extensive Psoriasis Treated with Topical Calcipotriol

Gumowski‐Sunek¹,

Rizzoli

Saurat³

1995

Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the study by Rico et al (8), 10 patients with psoriasis presented raised serum PTH levels during treatment with oral calcitriol. Other studies have failed to detect an alteration in PTH serum levels in the course of different treatments (9)(10)(11). In the present study, we measured the serum PTH levels in a larger group of patients with psoriasis and in comparison to a control group.…”

Section: Discussionmentioning

confidence: 99%

Serum Levels of Parathyroid Hormone and Parathyroid‐related Peptide in Psoriasis

Regaña¹,

Ezquerra²,

Millet³

2005

Acta Dermato-Venereologica

View full text Add to dashboard Cite

Psoriasis is a common skin disorder that may be triggered by hormonal disturbances, among other factors. Some studies have demonstrated an elevation of serum parathyroid hormone (PTH) levels in psoriasis and several other diseases of keratinization of unknown aetiology. PTH-related peptide (PTH-rp), on the other hand, is a potent inhibitor of epidermal cell growth factor and is not expressed in psoriatic skin. Serum levels of this peptide have not been reported in psoriasis. Immunoassay was used to measure serum PTH and PTH-rp in 22 patients with plaque-type psoriasis before and after treatment with mometasone furoate. Results were compared with a group of 20 healthy, non-psoriatic volunteers. Serum PTH levels were significantly elevated in the psoriatic group compared with the control group (p=0.001) and were significantly reduced after treatment (p=0.01). A correlation was found between pretreatment serum PTH levels and psoriasis area and severity scores (PASI) (r=0.42; p=0.01). In contrast, serum PTH-rp levels were not different between psoriatics and controls and were not affected by treatment. These findings indicate that serum PTH concentrations reflect disease activity in patients with psoriasis.

show abstract

“…Kalsiyum metabolizması üzerinde etkili olan D vitamini analoglarının psoriasis tedavisinde başarılı olduğu bildirilmektedir. Son yıllarda D vitamininin, sadece kemik gelişimi ve mineral metabolizmasında değil, aynı zamanda anti inflamatuvar ve immünmodülatör özelliklere de sahip olduğu gerçeğinin önemle vurgulanması psoriasis ve D vitamini üzerine yeniden dikkat çekilmesi gerektiğini düşündürmektedir (9,10). Psoriasis, her iki cinsi eşit sıklıkta etkiler ancak kadınlarda daha erken yaşta başlamaktadır (1).…”

Section: Introductionunclassified

Evaluation of Serum 25-Hydroxy Vitamin D Levels in Premenapousal Psoriasis Patients

Vural¹,

Topkarcı²,

Ersoy³

et al. 2014

Tod

View full text Add to dashboard Cite

SummaryObjective: To investigate the serum 25-hydroxy vitamin D levels in systemic treatment planned premenopausal psoriasis patients and compare it with the same age and sex matched healthy volunteers. Materials and Methods: Forty-one psoriasis patients and 57 healthy controls (total of 98) were included in the study. Serum 25-hydroxy vitamin D levels were compared between the two groups; also the relationship of disease activity and 25-hydroxy Vitamin D levels were examined in patients with psoriasis. Probability values of <0.05 were considered as statistically significant. Results: The mean age of patients with psoriasis and control groups were not statistically different (p>0.05). In addition, the mean 25-hydroxy vitamin D levels were not significantly different among the two groups (p>0.05). 25-hydroxy vitamin D levels were no significantly different in patients with and without psoriatic arthritis (p>0.05). No significant correlation was found between psoriasis area severity index PASI values, age or 25-hydroxy vitamin D levels (p>0.05). Conclusion:The low levels of vitamin D in population is reported to be common. In our study, similar low vitamin D levels were found in healthy volunteers and premenopausal psoriasis patients. Serum 25-hydroxy vitamin D levels were not correlated with disease activity in patients with psoriasis. Correlation between psoriasis, disease activity and vitamin D levels should be investigated in larger populations.

show abstract

Effects of Topical Calcipotriol on Calcium Metabolism in Psoriatic Patients: Comparison with Oral Calcitriol

Cited by 20 publications

References 6 publications

Oral Calcium Tolerance Test in Extensive Psoriasis Treated with Topical Calcipotriol

Oral Calcium Tolerance Test in Extensive Psoriasis Treated with Topical Calcipotriol

Serum Levels of Parathyroid Hormone and Parathyroid‐related Peptide in Psoriasis

Evaluation of Serum 25-Hydroxy Vitamin D Levels in Premenapousal Psoriasis Patients

Contact Info

Product

Resources

About